Travere Therapeutics (TVTX) Competitors $26.20 +0.70 (+2.75%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$26.04 -0.16 (-0.61%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. RVMD, GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, and TGTXShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Its Competitors Revolution Medicines Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics Revolution Medicines (NASDAQ:RVMD) and Travere Therapeutics (NASDAQ:TVTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Is RVMD or TVTX more profitable? Revolution Medicines has a net margin of 0.00% compared to Travere Therapeutics' net margin of -50.64%. Revolution Medicines' return on equity of -41.78% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -41.78% -35.63% Travere Therapeutics -50.64%-717.68%-30.69% Do institutionals & insiders hold more shares of RVMD or TVTX? 94.3% of Revolution Medicines shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 4.2% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings & valuation, RVMD or TVTX? Travere Therapeutics has higher revenue and earnings than Revolution Medicines. Travere Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$11.58M771.93-$600.09M-$4.50-10.63Travere Therapeutics$233.18M10.02-$321.55M-$2.04-12.84 Which has more volatility & risk, RVMD or TVTX? Revolution Medicines has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Do analysts rate RVMD or TVTX? Revolution Medicines currently has a consensus price target of $74.64, suggesting a potential upside of 56.09%. Travere Therapeutics has a consensus price target of $35.21, suggesting a potential upside of 34.41%. Given Revolution Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Revolution Medicines is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93Travere Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the media prefer RVMD or TVTX? In the previous week, Revolution Medicines had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 7 mentions for Revolution Medicines and 4 mentions for Travere Therapeutics. Revolution Medicines' average media sentiment score of 0.84 beat Travere Therapeutics' score of 0.46 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRevolution Medicines beats Travere Therapeutics on 13 of the 17 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.27B$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-12.8421.5785.3527.60Price / Sales10.02271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book34.4710.1413.016.76Net Income-$321.55M-$52.31M$3.30B$275.88M7 Day Performance8.18%5.14%4.34%2.81%1 Month Performance21.07%14.68%9.49%9.24%1 Year Performance48.95%30.98%84.83%35.42% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.3489 of 5 stars$26.20+2.7%$35.21+34.4%+72.3%$2.27B$233.18M-12.84460Analyst ForecastRVMDRevolution Medicines4.2719 of 5 stars$46.07+4.9%$74.64+62.0%-3.9%$8.21B$11.58M-10.24250Analyst ForecastGRFSGrifols3.7682 of 5 stars$9.93+1.1%$10.30+3.7%+9.9%$6.75B$7.81B8.4923,822Positive NewsAnalyst ForecastRYTMRhythm Pharmaceuticals3.5249 of 5 stars$100.64+1.5%$106.64+6.0%+108.4%$6.59B$130.13M-33.44140Positive NewsAnalyst ForecastRNAAvidity Biosciences2.2228 of 5 stars$42.63-0.7%$68.32+60.3%+4.2%$6.27B$10.73M-11.97190Analyst ForecastInsider TradeABVXAbivax2.9196 of 5 stars$83.33+0.6%$102.14+22.6%+847.5%$6.26BN/A0.0061Analyst ForecastLEGNLegend Biotech2.5959 of 5 stars$32.85-1.6%$74.22+125.9%-33.0%$6.16B$627.24M-37.332,609News CoverageAnalyst ForecastCYTKCytokinetics3.7433 of 5 stars$53.89+6.9%$75.71+40.5%+11.9%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent2.9495 of 5 stars$84.84+4.2%$119.50+40.9%-17.1%$5.87BN/A-17.3140Analyst ForecastAXSMAxsome Therapeutics4.782 of 5 stars$117.62+0.7%$177.86+51.2%+40.0%$5.83B$385.69M-23.20380Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionTGTXTG Therapeutics4.4414 of 5 stars$36.83+3.7%$48.00+30.3%+63.7%$5.63B$329M99.54290Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Revolution Medicines Competitors Grifols Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Abivax Competitors Legend Biotech Competitors Cytokinetics Competitors Nuvalent Competitors Axsome Therapeutics Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
